Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast
Infinity Pharmaceuticals (NASDAQ: INFI) will host a conference call on March 16, 2021, at 4:30 p.m. ET, to report Q4 and full-year 2020 financial results and provide updates on its lead drug, eganelisib. This oral immuno-oncology therapy is part of ongoing clinical studies, including MARIO-275, evaluating its combination with Opdivo in urothelial cancer. The conference call can be accessed via phone or a live webcast, with an archived version available for 30 days.
- Ongoing clinical studies for eganelisib in combination with major therapies like Opdivo, Tecentriq, and Abraxane.
- Potential first-in-class immuno-oncology treatment addressing immune suppression in cancer.
- None.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, March 16, 2021 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2020 financial results and provide an update on eganelisib development.
Conference Call & Webcast Details |
|
|
Date: |
March 16, 2021 |
|
Time: |
4:30 pm Eastern Time |
|
Toll Free: |
(877) 316-5293 |
|
International: |
(631) 291-4526 |
|
Conference ID: |
7174736 |
|
Webcast: |
A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. An archived version of the webcast will be available on Infinity's website for 30 days.
About Infinity and eganelisib
Infinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.
Doxil® is a registered trademark of Baxter Healthcare Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005959/en/
FAQ
When will Infinity Pharmaceuticals report its Q4 and full-year 2020 financial results?
What is eganelisib and its purpose?
How can I access the conference call and webcast for Infinity Pharmaceuticals?
What studies are being conducted for eganelisib?
